<DOC>
	<DOCNO>NCT02584608</DOCNO>
	<brief_summary>This study open label use ACTIMMUNE patient Autosomal Dominant Osteopetrosis Type 2 ( ADO2 ) . Effects treatment evaluate 14 week ACTIMMUNE bone resorption marker . This study treat 12 patient ADO2 recruit Indiana University Riley Hospital Children Indiana University Health .</brief_summary>
	<brief_title>Use ACTIMMUNE Patients With ADO2</brief_title>
	<detailed_description>This single center , open-label , dose-escalation study evaluate efficacy , define biochemical endpoint , safety profile ACTIMMUNE ADO2 subject . The investigator treat 12 ADO2 subject ( child adults age 3-65 ) Actimmune® via dose escalation protocol dose 50 µg/m2 subcutaneously three time per week ( TIW ) 8 week . If serum CTX increase 25 % week 8 , dose increase 100 µg/m2 subcutaneously TIW . Individual subject ACTIMMUNE administration increase bone resorption marker 14 week trial eligible 1 year extension trial .</detailed_description>
	<mesh_term>Osteopetrosis</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>1 . Subject diagnose clinically significant ADO2 determine investigator . Individuals screen either diagnose osteopetrosis clinical phenotype and/or family history consistent ADO2 , tell abnormally high bone density ( &gt; 3SD mean age sex ) , clinical presentation consistent ADO2 . Initial contact member ADO2 kindred know disease . 2 . Provide write informed consent competent adult minor provide write assent ( appropriate ) write informed consent legally authorize representative nature study explain , prior researchrelated procedure 3 . Ages 3 65 year inclusive . 4 . Willing use reliable method contraception [ i.e . oral patch hormonal contraceptive , intrauterine device , physical barrier method , tubal ligation hysterectomy , vasectomy ( partner ) abstinence ] throughout study 30 day last dose study drug . 1 . Any unstable illness investigator 's opinion precludes participation study . 2 . Serum calcium &gt; 10.6 mg/dl screening . 3. eGFR use MDRD equation adult ( modify Schwartz equation child ) &lt; 35 ml/min/1.73m2 . 4 . Nephrocalcinosis screen ultrasound Grade 3 high [ 18 ] . Subjects grade 3 high nephrocalcinosis exclude anticipate use study drug increase bone resorption , result increase urinary calcium excretion , could , potentially , lead worsen nephrocalcinosis . The grade scale list : 0 = Normal 1 . = Faint hyperechogenic rim around side tip medullary pyramid 2 . = More intense echogenic rim echo faintly fill entire medullary pyramid 3 . = Intense echo throughout medullary pyramid 4 . = Solitary focus echo tip medullary pyramid/nephrolithiasis 5 . Use investigational product ( drug device ) within 30 day prior randomization . 6 . Subject report history hepatitis C. 7 . A recent ( past 5 year ) history alcoholism intravenous drug abuse . 8 . History hypersensitivity IFNɣ E. coliderived product . 9 . History liver disease evidence laboratory result Screening ( aspartate aminotransferase [ AST ] alanine aminotransferase [ ALT ] &gt; 2x upper limit normal ) , except opinion investigator liver disease cause extra medullary hematopoiesis . 10 . Pregnant nursing woman plan become pregnant study .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>